Late stage pipeline

Focus on Innovation and Science to unlock mid-term potential

Pipeline updated as of March 2023

Molecule / Project
Indication
Expected Launch
Preclinical Phase Phase I Phase II Phase III Under Registration Geography
Tribanibulin
Large field		 Actinic keratosis US 2024
90 Under registration
U.S. U.S.
Tribanibulin
Large field		 Actinic keratosis EU 2026
75 Fase3
EU EU
Sarecycline Acne 2024
80 Fase3
China China
Efinaconazole Onychomycosis 2024
95 Under registration
EU EU
ALM401 Autoinmune dermatology TBD
45 Fase2
Worldwide Worldwide
ALM27134 Autoinmune dermatology TBD
30 Fase1
Worldwide Worldwide
ALM223
Early stage		 Autoinmune dermatology TBD
19 Preclinical Phase
Worldwide Worldwide*

Actinic keratosis Tribanibulin
Large field US 2024 Under registration U.S.

Actinic keratosis Tribanibulin
Large field EU 2026 Fase3 EU

Acne Sarecycline 2024 Fase3 china

Onychomycosis Efinaconazole 2024 Under registration EU

Autoinmune dermatology ALM401 TBD Fase2 worldwide

Autoinmune dermatology ALM27134 TBD Fase1 worldwide

Autoinmune dermatology ALM223
Early stage TBD Preclinical Phase worldwide_exchina ‏‏* Worldwide ex-Greater China